TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9814837

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight apo(a) isoforms
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: High-molecular-weight apo(a) isoforms
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Proteinuric patients
Number of subjects: 58

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 58
Study: 7705112

Group type: EXPERIMENTAL
Intervention: Clarithromycin alone (n = 14)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Clarithromycin in combination with rifampin (n = 8)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Clarithromycin in combination with other drugs (aminoglycoside, quinolone, clofazimine, isoniazid, ethambutol, pyrazinamide, minocycline)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Clarithromycin (30 mg/kg daily)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Adverse effects of clarithromycin
Number of subjects: 45
Study: 2552051

Group type: EXPERIMENTAL
Intervention: Four-week career decision-making course
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 42
Study: 31121557

Group type: EXPERIMENTAL
Intervention: Print-based intervention supported by Internet tools
Number of subjects: 207

Group type: COMPARATOR
Intervention: Standard letter recommendation
Number of subjects: 207
Study: 28460892

Group type: EXPERIMENTAL
Intervention: Erenumab 70 mg
Number of subjects: 667

Group type: EXPERIMENTAL
Intervention: Erenumab 140 mg
Number of subjects: 667

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 667
Study: 26049188

Group type: EXPERIMENTAL
Intervention: Rhubarb decontaminate group (15-20 g aqueous extract by gastric tube, enema, or peros, twice a day)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Traditional decontaminate group (glycerine enema or glycerol enema, twice a day)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Blank control group (no treatment)
Number of subjects: 57
Study: 22679301

Group type: EXPERIMENTAL
Intervention: Combination therapy (methotrexate (MTX) + sulfasalazine + hydroxychloroquine) with intramuscular glucocorticoids (GCs)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Combination therapy with oral GC tapering scheme
Number of subjects: 281

Group type: COMPARATOR
Intervention: MTX with oral GCs
Number of subjects: 281
Study: 21385466

Group type: EXPERIMENTAL
Intervention: Holistic therapy (HT) consisting of light physical exercise sessions and a mental stress reduction program administered for two weeks.
Number of subjects: 117

Group type: COMPARATOR
Intervention: Usual care (UC) provided to the control group.
Number of subjects: 117
Study: 18845781

Group type: EXPERIMENTAL
Intervention: Speed endurance training (SET; n = 9)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (Con; n = 8)
Number of subjects: 17
Study: 16915380

Group type: EXPERIMENTAL
Intervention: Lorazepam (0.038 mg/kg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 15299181

Group type: EXPERIMENTAL
Intervention: RT with DDP (100 mg/m2 on d 2, 22, 42)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: RT with Cb (7 AUC on d 2, 22, 42)
Number of subjects: 124

Group type: COMPARATOR
Intervention: RT alone (70 Gy)
Number of subjects: 124
Study: 11977324

Group type: EXPERIMENTAL
Intervention: Biliary gastritis with Helicobacter pylori infection
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Erosive gastritis with Helicobacter pylori infection
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Biliary gastritis without Helicobacter pylori infection
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Biliary gastritis and erosive gastritis
Number of subjects: 50
Study: 9043505

Group type: EXPERIMENTAL
Intervention: Infusion method
Number of subjects: 118

Group type: COMPARATOR
Intervention: Midnight removal of the catheter
Number of subjects: 118

Group type: COMPARATOR
Intervention: Dawn removal of the catheter
Number of subjects: 118
Study: 7940136

Group type: EXPERIMENTAL
Intervention: Betaxolol 0.5%
Number of subjects: 19

Group type: COMPARATOR
Intervention: Timolol 0.5%
Number of subjects: 19
Study: 3189143

Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 30
Study: 31085026

Group type: EXPERIMENTAL
Intervention: Core needle biopsy (CNB) for myxoid tumors
Number of subjects: 369

Group type: COMPARATOR
Intervention: Core needle biopsy (CNB) for non-myxoid tumors
Number of subjects: 369
Study: 28382800

Group type: EXPERIMENTAL
Intervention: FloSeal application on one side of the pelvis
Number of subjects: 37
Study: 25293387

Group type: EXPERIMENTAL
Intervention: 20 mg enalapril at bedtime for 12 weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 20 mg enalapril in the morning for 12 weeks
Number of subjects: 24
Study: 22565518

Group type: EXPERIMENTAL
Intervention: Round bur
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Air polishing
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Air abrasion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pumice slurry
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bristle brush
Number of subjects: 60

Group type: COMPARATOR
Intervention: Longer etching time
Number of subjects: 60
Study: 20035531

Group type: EXPERIMENTAL
Intervention: Stapled anopexy
Number of subjects: 207

Group type: COMPARATOR
Intervention: Diathermy excision (Milligan‐Morgan haemorrhoidectomy)
Number of subjects: 207
Study: 17875033

Group type: EXPERIMENTAL
Intervention: Serotonergic antidepressants (4-month prophylactic therapy)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (healthy subjects, N=50)
Number of subjects: 45
Study: 15713522

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (cisplatin 50 mg/m2 days 1, 8 and vinorelbine 25 mg/m2 days 1, 8, 15, 22 for four cycles)
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 424
Study: 11919666

Group type: EXPERIMENTAL
Intervention: Glucose administration (25 g)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspartame solution (control)
Number of subjects: 0
Study: 10430690

Group type: EXPERIMENTAL
Intervention: Stapled laparoscopic TAPP inguinal hernia repair
Number of subjects: 502

Group type: COMPARATOR
Intervention: Nonstapled laparoscopic TAPP inguinal hernia repair
Number of subjects: 502
Study: 7586938

Group type: EXPERIMENTAL
Intervention: Empirin with codeine
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Mersyndol
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 2315472

Group type: EXPERIMENTAL
Intervention: RASE technique
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional SE technique
Number of subjects: 20
Study: 7244965

Group type: EXPERIMENTAL
Intervention: Sump drainage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Closed static drainage
Number of subjects: 0
Study: 30213672

Group type: EXPERIMENTAL
Intervention: Preoperative physical activity level
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Self‐efficacy for exercise
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Preoperative disability
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Pain catastrophizing
Number of subjects: 118
Study: 27633962

Group type: EXPERIMENTAL
Intervention: Terlipressin
Number of subjects: 84

Group type: COMPARATOR
Intervention: Noradrenaline
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Lactate clearance
Number of subjects: 84
Study: 25948287

Group type: EXPERIMENTAL
Intervention: healthy lifestyle psychoeducational program + improved primary care usual treatment (ITAU)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: focused program on positive affect promotion + ITAU
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: mindfulness + ITAU
Number of subjects: 240

Group type: COMPARATOR
Intervention: ITAU
Number of subjects: 240
Study: 23579244

Group type: EXPERIMENTAL
Intervention: Patient Health Questionnaire‐9 (PHQ‐9)
Number of subjects: 1392

Group type: EXPERIMENTAL
Intervention: PRAMS‐6
Number of subjects: 1392

Group type: EXPERIMENTAL
Intervention: PRAMS‐3D
Number of subjects: 1392

Group type: EXPERIMENTAL
Intervention: PRAMS‐3A
Number of subjects: 1392

Group type: COMPARATOR
Intervention: Structured Clinical Interview for the DSM‐IV (SCID)
Number of subjects: 1392

Group type: COMPARATOR
Intervention: Hamilton Rating Scale for Depression
Number of subjects: 1392
Study: 21262099

Group type: EXPERIMENTAL
Intervention: 200 μg of mometasone furoate (MF)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 20144173

Group type: EXPERIMENTAL
Intervention: Red clover-derived isoflavone medication
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-medication group
Number of subjects: 40
Study: 17710979

Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural analgesia with intrathecal fentanyl 25 mcg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Epidural analgesia with bupivacaine 0.25% 10 ml
Number of subjects: 50
Study: 16524973

Group type: EXPERIMENTAL
Intervention: Chemoradiation followed by surgery (arm A)
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Continuation of chemoradiation (arm B)
Number of subjects: 451
Study: 12658373

Group type: EXPERIMENTAL
Intervention: Entacapone 200 mg
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study: 10551072

Group type: EXPERIMENTAL
Intervention: Mandibular overdenture supported by 2 implants with ball attachments
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Mandibular overdenture supported by 2 implants with an interconnecting bar
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Mandibular overdenture supported by 4 interconnected implants
Number of subjects: 110
Study: 8903117

Group type: EXPERIMENTAL
Intervention: Intrapulmonary insulin (100 U ml-1 as an aerosol by oral inhalation after a 12-h fasting)
Number of subjects: 12
Study: 1830277

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Ipratropium
Number of subjects: 19
Study: 6401551

Group type: EXPERIMENTAL
Intervention: Slow sodium tablets
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Slow sodium tablets and Placebo tablets
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Moderate dietary sodium restriction
Number of subjects: 18
Study: 30814418

Group type: EXPERIMENTAL
Intervention: Roasted barley extract (RBE) containing cyclo(d‐Phe‐l‐Pro)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Roasted barley extract (RBE) containing cyclo(d‐Phe‐l‐Pro) in male participants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo in male participants
Number of subjects: 0
Study: 27539539

Group type: EXPERIMENTAL
Intervention: High-fat, nondairy meal 4 hours before dosing
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: High-fat, nondairy meal 2 hours before dosing
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: High-fat meal containing dairy 2 hours before dosing
Number of subjects: 31

Group type: COMPARATOR
Intervention: Fasted state
Number of subjects: 31
Study: 26053288

Group type: EXPERIMENTAL
Intervention: 200 mg of caffeine
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 23916502

Group type: EXPERIMENTAL
Intervention: Aclidinium 200 μg
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Aclidinium 400 μg
Number of subjects: 605

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 605
Study: 21697773

Group type: EXPERIMENTAL
Intervention: CNI elimination (everolimus with CNI elimination)
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: CNI minimization
Number of subjects: 394

Group type: COMPARATOR
Intervention: Control (continued CNI unchanged)
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: CNI elimination (in patients with baseline CrCl > 50 mL/min)
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: CNI minimization (in patients with baseline CrCl > 50 mL/min)
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 394
Study: 20166586

Group type: EXPERIMENTAL
Intervention: 200 mg emtricitabine
Number of subjects: 43
Study: 16805744

Group type: EXPERIMENTAL
Intervention: One-man method
Number of subjects: 80

Group type: COMPARATOR
Intervention: Two-man method
Number of subjects: 80
Study: 15530762

Group type: EXPERIMENTAL
Intervention: Video colposcopy intervention
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 81
Study: 12964332

Group type: EXPERIMENTAL
Intervention: Occlusive dressings (Comfeel Plus, DuoDerm CGF, OpSite)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Air exposure
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Occlusive dressings
Number of subjects: 10
Study: 9046892

Group type: EXPERIMENTAL
Intervention: Intensive intervention (n = 561)
Number of subjects: 2024

Group type: EXPERIMENTAL
Intervention: Minimal intervention (n = 473)
Number of subjects: 2024

Group type: COMPARATOR
Intervention: Usual care (n = 990)
Number of subjects: 2024
Study: 8378746

Group type: EXPERIMENTAL
Intervention: Very long-chain n-3 fatty acids (0.65 g day-1)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control oil
Number of subjects: 24
Study: 3535007

Group type: COMPARATOR
Intervention: Cimetidine (800 mg) plus antacid
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Pirenzepine (100 mg) plus antacid
Number of subjects: 55
Study: 29149437

Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose [15 mg/kg (up to 750 mg)], intravenously on study days 0 and 5
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (15 cc normal saline), intravenously on study days 0 and 5
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 27098300

Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training after AbobotulinumtoxinA injection
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (only AbobotulinumtoxinA injection)
Number of subjects: 22
Study: 26178888

Group type: EXPERIMENTAL
Intervention: In-home telerehabilitation
Number of subjects: 205

Group type: COMPARATOR
Intervention: Face-to-face home visit
Number of subjects: 205
Study: 23945458

Group type: EXPERIMENTAL
Intervention: Pramipexole (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (n = 30)
Number of subjects: 60
Study: 21172701

Group type: EXPERIMENTAL
Intervention: Local anesthesia and sedation (EMLA 5% cream, midazolam/nitrous oxide)
Number of subjects: 76

Group type: COMPARATOR
Intervention: General anesthesia with or without penile block (sevoflurane, ropivacaine)
Number of subjects: 76
Study: 18489932

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents in patients with normal BMI (<25 kg/m²)
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents in overweight patients (≥25 and ≤30 kg/m²)
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents in obese patients (>30 kg/m²)
Number of subjects: 607
Study: 17166340

Group type: EXPERIMENTAL
Intervention: tesaglitazar 0.5 mg
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: tesaglitazar 1.0 mg
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: tesaglitazar 2.0 mg
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: tesaglitazar 3.0 mg
Number of subjects: 500

Group type: COMPARATOR
Intervention: pioglitazone 45 mg
Number of subjects: 500

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 500
Study: 12648197

Group type: EXPERIMENTAL
Intervention: N2O
Number of subjects: 30

Group type: COMPARATOR
Intervention: Air
Number of subjects: 30
Study: 12589230

Group type: EXPERIMENTAL
Intervention: Glyburide/metformin combination therapy
Number of subjects: 92
Study: 10548357

Group type: EXPERIMENTAL
Intervention: 200 mg cimetidine (Tagamet HB)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Multiple doses of Mylanta (initial 17.5-ml dose with additional doses as needed)
Number of subjects: 20
Study: 8740603

Group type: EXPERIMENTAL
Intervention: High-intensity TENS
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low-intensity TENS
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study: 1918785

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (200 mg every 12 hours or 400 mg every 12 hours during acute phase, followed by 750 mg orally every 12 hours during convalescence phase)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ceftriaxone (2 g every 24 hours during acute phase, followed by 1 g intramuscularly every 24 hours during convalescence phase)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 50
Study: 6821904

Group type: EXPERIMENTAL
Intervention: Dopamine, 15 micrograms/kg/min
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Dobutamine, 15 micrograms/kg/min
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Dopamine and Dobutamine combination, 7.5 micrograms/kg/min each
Number of subjects: 8
Study: 31473167

Group type: EXPERIMENTAL
Intervention: VRC07-523LS (1 mg/kg intravenous)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: VRC07-523LS (5 mg/kg intravenous)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: VRC07-523LS (20 mg/kg intravenous)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: VRC07-523LS (40 mg/kg intravenous)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: VRC07-523LS (5 mg/kg subcutaneous)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: VRC07-523LS (20 mg/kg intravenous, 3 doses at 12-week intervals)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: VRC07-523LS (5 mg/kg subcutaneous, 3 doses at 12-week intervals)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: VRC07-523LS (all groups)
Number of subjects: 26
Study: 29693495

Group type: EXPERIMENTAL
Intervention: Nicotine patch (n=37)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo patch (n=44)
Number of subjects: 81
Study: 26822749

Group type: EXPERIMENTAL
Intervention: Phenytoin (4 mg/kg or 6 mg/kg per day for 3 months)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86

Group type: COMPARATOR
Intervention: Phenytoin vs Placebo
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 86
Study: 24449739

Group type: EXPERIMENTAL
Intervention: Cervical cerclage
Number of subjects: 24

Group type: COMPARATOR
Intervention: Expectant management (control)
Number of subjects: 24
Study: 22855753

Group type: EXPERIMENTAL
Intervention: Insecticide-treated plastic sheeting (ITPS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated polyethylene sheeting (UPS)
Number of subjects: 0
Study: 20712506

Group type: EXPERIMENTAL
Intervention: Interdependent self‐construal priming
Number of subjects: 58

Group type: COMPARATOR
Intervention: Independent self‐construal priming
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Chronic promotion regulatory focus: high
Number of subjects: 58

Group type: COMPARATOR
Intervention: Chronic promotion regulatory focus: low
Number of subjects: 58
Study: 17573387

Group type: EXPERIMENTAL
Intervention: 150 mg/day UDCA
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: 600 mg/day UDCA
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: 900 mg/day UDCA
Number of subjects: 596

Group type: COMPARATOR
Intervention: Control (no UDCA)
Number of subjects: 596
Study: 15728282

Group type: EXPERIMENTAL
Intervention: Interferon beta‐1b 250 microg
Number of subjects: 205

Group type: COMPARATOR
Intervention: Interferon beta‐1b 50 microg
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Interferon beta‐1b
Number of subjects: 205
Study: 11888459

Group type: EXPERIMENTAL
Intervention: Partial matrix excision (matrix group)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Phenolization (phenol group)
Number of subjects: 58
Study: 10723507

Group type: EXPERIMENTAL
Intervention: Didanosine once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Didanosine once daily in combination with other drugs
Number of subjects: 0
Study: 7646766

Group type: EXPERIMENTAL
Intervention: Chymotrypsin-galactose (CG) treatment of sperm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Culture medium treatment of sperm
Number of subjects: 0
Study: 2649628

Group type: EXPERIMENTAL
Intervention: Computer‐assisted CBM group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Noncomputer CBM group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CBM groups (computer‐assisted and noncomputer)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Contrast group
Number of subjects: 30
Study: 333082

Group type: EXPERIMENTAL
Intervention: 0.25% phenylephrine hydrochloride
Number of subjects: 45

Group type: COMPARATOR
Intervention: 0.5% phenylephrine hydrochloride
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 29886273

Group type: EXPERIMENTAL
Intervention: Treatment (not specified)
Number of subjects: 140
Study: 28179035

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of the ventral anterior limb of the internal capsule (vALIC)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Active stimulation
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 25
Study: 25535650

Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) 50 mg once weekly (QW)
Number of subjects: 372
Study: 23981017

Group type: EXPERIMENTAL
Intervention: Rituximab and prednisolone combined (N = 32)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Prednisolone monotherapy (N = 32)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 64
Study: 21380980

Group type: EXPERIMENTAL
Intervention: 8-week (aerobic+strength) exercise training program (3 sessions/week, 90 min/session)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 8-week (aerobic+strength) exercise training program
Number of subjects: 16
Study: 18312755

Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein (hs-CRP)
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: White blood cell (WBC) count
Number of subjects: 490
Study: 16564594

Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy (IMRT)
Number of subjects: 22